Greenfield Savings Bank Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Greenfield Savings Bank reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,140 shares of the biopharmaceutical company’s stock after selling 560 shares during the period. Greenfield Savings Bank’s holdings in Gilead Sciences were worth $567,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in GILD. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at approximately $25,000. Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $33,000. Finally, Quarry LP purchased a new stake in Gilead Sciences during the 2nd quarter worth about $43,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GILD shares. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $87.00 to $113.00 in a report on Friday. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $89.94 on Tuesday. The firm’s 50 day simple moving average is $91.94 and its two-hundred day simple moving average is $83.54. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $112.09 billion, a P/E ratio of 999.33, a P/E/G ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock worth $41,902,086 over the last 90 days. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.